Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 33, Issue 1, 2016, Pages 75-82

  Van Manen, Mirjam J G ^a   Wapenaar, Monique ^a   Strookappe, Bert ^b,c   Drent, Marjolein ^b,d,e   Elfferich, Marjon ^b,c   De Vries, Jolanda ^b,f   Gosker, Harry R ^g   Birring, Surinder S ^h   Patel, Amit S ^h   Van Den Toorn, Leon ^a   Van Den Blink, Bernt ^a   Boomars, Karin ^a   Hoitsma, Elske ^c,i   Wijsenbeek, Marlies S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ild care foundation research team   (Netherlands)

^c GELDERSE VALLEI HOSPITAL   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f TILBURG UNIVERSITY   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ Alrijne Hospital   (Netherlands)

Author keywords

Health status; Quality of life; Questionnaire; Sarcoidosis

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; CORRELATION COEFFICIENT; EYE DISEASE; FEMALE; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; KING SARCOIDOSIS QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT REPEATABILITY; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SARCOIDOSIS; SKIN DISEASE; VALIDATION STUDY; WIORLD HEALTH ORGANIZATION QUALITY OF LIFE BREF QUESTIONNAIRE; NETHERLANDS; PUBLICATION; SELF REPORT;

FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; SARCOIDOSIS; SELF REPORT; TRANSLATIONS;

EID: 84963984762     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet 2014 Mar 29; 383(9923): 1155-67.
2. Victorson DE, Cella D, Grund H, Judson MA. A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res 2014 Feb; 23(1): 89-101.
3. Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries, J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998 Mar; 15(1): 59-66.
4. Vorselaars AD, Cremers JP, Grutters JC, Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? Curr Opin Pulm Med 2014 Sep; 20(5): 479-87.
5. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Nov; 44(5): 1296-307.
6. Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med 2013 Sep; 19(5): 474-9.
7. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998 May; 28(3): 551-8.
8. Alilovic M, Peros-Golubicic T, Radosevic-Vidacek B, et al. WHOQOL-bREF questionnaire as a measure of quality of life in sarcoidosis. Coll Antropol 2013 Sep; 37(3): 701-6.
9. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 Jun; 30(6): 473-83.
10. Bourbonnais JM, Malaisamy S, Dalal BD, Samarakoon PC, Parikh SR, Samavati L. Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012; 10: 67.
11. Elfferich MD, De Vries, J, Drent M. Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2011 Jul; 28(1): 65-71.
12. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: A randomized, double-blind pilot study. Mol Med 2012; 18: 1430-6.
13. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013 Jan; 68(1): 57-65.
14. Acquadro C, Conway K, Hareendran A, Aaronson N, European Regulatory I, Quality of Life Assessment G. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health 2008 May-Jun; 11(3): 509-21.
15. U.S. Department of Health and Human services Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009.
16. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
17. Michielsen HJ, De Vries, J, Van Heck, GL, Van de Vijver, FJ, Sijtsma K. Examination of the Dimensionality of Fatigue: The Construction of the Fatigue Assessment Scale (FAS). Eur J Psychol Assess. 2004; 20(1): 39-48.
18. Hoitsma E, De Vries, J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med 2011 Jan; 105(1): 95-100.
19. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries, J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006 Oct; 130(4): 989-94.
20. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19(3): 210-6.
21. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001 Jul; 119(7): 1050-8.
22. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011 Dec; 20(10): 1727-36.
23. Fletcher KE, French CT, Irwin RS, Corapi KM, Norman GR. A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. J Clin Epidemiol 2010 Oct; 63(10): 1123-31.
24. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: A review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009; 17(3): 163-70.
25. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999 Aug; 160(2): 736-55.
26. Patel AS, Siegert RJ, Bajwah S, et al. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. J Clin Epidemiol. 2015 Apr 10.
27. Sinha A, Bajwah S, Gosker HR, et al. A comparison of two scoring methods for the King's Sarcoidosis Questionnaire. Abstract accepted for the ERS 2015.
28. De Vries, J, Van Heck, GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health 1999; 30(2): 99-114.
29. Obaseki DO, Erhabor GE, Awopeju OF, Obaseki JE, Adewole OO. Determinants of health related quality of life in a sample of patients with chronic obstructive pulmonary disease in Nigeria using the St. George's respiratory questionnaire. Afr Health Sci 2013 Sep; 13(3): 694-702.
30. Drent M, Lower EE, De Vries, J. Sarcoidosis-associated fatigue. Eur Respir J 2012 Jul; 40(1): 255-63.
31. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31(1): 19-27.
32. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: A new measure of health-related quality of life. Am J Respir Crit Care Med 2003 Aug 1; 168(3): 323-9.
33. Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med 2015 Apr 1; 191(7):786-95.